Home » Stocks » LOGC

LogicBio Therapeutics, Inc. (LOGC)

Stock Price: $4.26 USD 0.03 (0.71%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 135.09M
Revenue (ttm) 2.89M
Net Income (ttm) -33.45M
Shares Out 31.93M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $4.26
Previous Close $4.23
Change ($) 0.03
Change (%) 0.71%
Day's Open 4.29
Day's Range 4.15 - 4.34
Day's Volume 154,539
52-Week Range 3.72 - 9.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LEXINGTON, Mass., July 8, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...

3 weeks ago - PRNewsWire

LEXINGTON, Mass., June 2, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene editing and gene delivery platforms to address rare an...

1 month ago - PRNewsWire

LEXINGTON, Mass., June 1, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...

1 month ago - PRNewsWire

LEXINGTON, Mass., May 19, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...

2 months ago - PRNewsWire

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical-stage genetic medicine company pioneering gene delivery and gene editing pl...

2 months ago - PRNewsWire

LEXINGTON, Mass., May 10, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare an...

2 months ago - PRNewsWire

LEXINGTON, Mass., May 4, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and...

2 months ago - PRNewsWire

LEXINGTON, Mass., May 3, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and...

2 months ago - PRNewsWire

Arix Bioscience PLC (LON:ARIX) said portfolio company LogicBio Therapeutics, Inc. (NASDAQ:LOGC) has signed a strategic collaboration with CANbridge Pharmaceuticals as well as a research partnership with...

3 months ago - Proactive Investors

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--CANbridge Pharmaceuticals Announces Rare Disease Collaboration with LogicBio and Licenses on Gene Editing & Delivery, Worldwide and in Greater China

3 months ago - Business Wire

LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...

3 months ago - PRNewsWire

LEXINGTON, Mass., March 30, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare ...

3 months ago - PRNewsWire

LEXINGTON, Mass., March 15, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a clinical- stage genetic medicine company pioneering gene delivery and gene editing...

4 months ago - PRNewsWire

LEXINGTON, Mass., Feb. 26, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare a...

5 months ago - PRNewsWire

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Other stocks mentioned: APRN, CACC, CLH, MGTA
7 months ago - Zacks Investment Research

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment ...

8 months ago - Insider Monkey

Gene-editing concern LogicBio Therapeutics, Inc. has lost ~$90 million of market cap since an IND clinical hold was placed on its LB-001 candidate in February 2020. The hold was lifted in August 2020 wi...

8 months ago - Seeking Alpha

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery today anno...

8 months ago - GlobeNewsWire

- IND for LB-001 in methylmalonic acidemia (MMA) cleared in August 2020 , with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 - Fast Track designation for LB-001 in MMA r...

8 months ago - GlobeNewsWire

Fast Track designation facilitates development of new therapies that treat serious conditions and fulfill unmet needs for patients Fast Track designation facilitates development of new therapies that tr...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery...

9 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery...

9 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 30, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted deliver...

9 months ago - GlobeNewsWire

LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pat...

10 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 25, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pat...

10 months ago - GlobeNewsWire

– LogicBio’s First IND Clearance Leveraging GeneRide, an In Vivo Homologous Recombination-based Genome Editing Platform –

11 months ago - GlobeNewsWire

FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients FDA Clears IND Application for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Pat...

11 months ago - GlobeNewsWire

LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

NEW YORK, May 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of LogicBio Therapeutics, Inc. (NASDAQ: LOGC) between December 3, 2018 and ...

1 year ago - PRNewsWire

CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pat...

1 year ago - GlobeNewsWire

LogicBio: A Speculative Buy For Their GeneRide Platform Based Gene Therapies

1 year ago - Seeking Alpha

CAMBRIDGE, Mass., Feb. 10, 2020 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pati...

1 year ago - GlobeNewsWire

– Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients – – Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 – – Established research collaboration wi...

1 year ago - GlobeNewsWire

CAMBRIDGE, Mass., Dec. 17, 2019 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric pati...

1 year ago - GlobeNewsWire

About LOGC

LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene thera... [Read more...]

Industry
Biotechnology
IPO Date
Oct 19, 2018
CEO
Frederic Chereau
Employees
39
Stock Exchange
NASDAQ
Ticker Symbol
LOGC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for LOGC stock is "Strong Buy." The 12-month stock price forecast is 19.00, which is an increase of 346.01% from the latest price.

Price Target
$19.00
(346.01% upside)
Analyst Consensus: Strong Buy